22:41 , Jan 28, 2019 |  BC Extra  |  Preclinical News

Unfolded protein response activates MYC in prostate cancer

A European team has linked the unfolded protein response to MYC signaling, lending weight to oncology strategies targeting the IRE1/XBP1 pathway, and identified prostate cancer as another indication for XBP1 inhibitors. A U.S. team including...
18:39 , Oct 18, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Ovarian cancer Patient sample and mouse studies suggest T cell-specific inhibition of XBP1 or IRE1 could help treat ovarian cancer. In tumor and ascites samples from patients, high T cell expression of XBP1 was...
18:33 , Oct 10, 2018 |  BC Extra  |  Preclinical News

Quentis links ER stress, mitochondrial dysfunction with antitumor T cell activity

Researchers at Quentis Therapeutics Inc. (New York, N.Y.), Weill Cornell Medicine and Dana-Farber Cancer Institute uncovered a new mechanism of tumor immune evasion in which endoplasmic reticulum stress limits mitochondrial respiration and antitumor activity in...
17:42 , Mar 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; breast cancer; chronic lymphocytic leukemia (CLL); lymphoma; neuroendocrine tumors Patient sample, cell culture and mouse studies suggest inhibiting XBP1 or its activator IRE1 could help treat MYC- or MYCN-driven cancers. In breast cancer...
20:45 , Oct 31, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Colorectal cancer Patient sample, cell culture and mouse studies suggest inhibiting an unspliced XBP1 variant could help treat colorectal cancer. In tissue samples from patients, levels of an unspliced XBP1 variant were higher in...
20:02 , Dec 6, 2016 |  BC Week In Review  |  Clinical News

PVX-410: Ph Ib started

OncoPep said investigators began an open-label, U.S. Phase Ib trial to evaluate intramuscular PVX-410 plus IV durvalumab (MEDI4736) in about 20 patients. Patients will receive PVX-410 every 2 weeks and durvalumab given with the fourth...
20:00 , Dec 6, 2016 |  BC Week In Review  |  Clinical News

Durvalumab: Ph Ib started

OncoPep Inc. (North Andover, Mass.) said investigators began an open-label, U.S. Phase Ib trial to evaluate intramuscular PVX-410 plus IV durvalumab in about 20 patients. Patients will receive PVX-410 every 2 weeks and durvalumab given...
11:43 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

PVX-410: Ph Ib started

OncoPep began an open-label, U.S. Phase Ib trial to compare PVX-410 plus IV durvalumab ( MEDI4736 ) with or without Revlimid lenalidomide vs. durvalumab alone in about 26 patients. Patients will receive PVX-410 and Revlimid...
11:43 , Dec 1, 2016 |  BC Week In Review  |  Clinical News

Durvalumab: Ph Ib started

OncoPep Inc. (North Andover, Mass.) began an open-label, U.S. Phase Ib trial to compare PVX-410 plus IV durvalumab with or without Revlimid lenalidomide vs. durvalumab alone in about 26 patients. Patients will receive PVX-410 and...
07:00 , Jun 25, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: X-box binding protein 1 (XBP1)

Cancer INDICATION: Ovarian cancer Mouse studies suggest inhibiting XBP1 could help treat ovarian cancer. In ovarian cancer patients and a mouse model of the disease, levels of XBP1 transcripts were higher in tumor-infiltrating dendritic cells...